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Purpose. To report a case of microbial keratitis caused by Pseudomonas aeruginosa treated with a combination of acetazolamide
and ceftazidime. Methods.C a s er e p o r t .Results. We report the case of a 17-year-old contact lens-wearing female who developed
severe keratitis due to Pseudomonas aeruginosa temporarily healed with topical fortiﬁed antibiotic eye drops. After few days, the
patient relapsed, and topical and intravenous ceftazidime were added. Concomitantly, oral administration of acetazolamide was
prescribed. This carbonic anhydrase inhibitor was added to the antibiotic regimen in order to decrease the anterior chamber pH,
and then, the ceftazidime ionization. By lowering the state of ionization of the antibiotic in the aqueous humor, its concentration
was increased. This was conﬁrmed by an improvement of the patient within few days and a rapid eradication of the infection.
Conclusion.ThisistheﬁrstreportedcaseofkeratitiscausedbyP. aeruginosa successfullytreatedusingacetazolamideasanenhancer
of ceftazidime eﬀectiveness.
Copyright © 2009 Benoit Hue et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.CaseReport
A 17-year-old woman was referred with a 48-hour history
of a painful left eye as a consequence of a severe keratitis
most likely of bacterial aetiology. Pain started after bathing
in a public swimming pool while continuing to wear her
contact lenses on a daily basis. On presentation, the left
eye visual acuity was 2.3 LogMar (L). An extensive necrotic
stromal inﬁltrate was observed in the cornea with a dense
hypopyon. The corneal ulcer size was 7mm × 7mm. Cornea
scrapings were performed for microbiological staining and
inoculated for culture. On admission, topical treatment
included vancomycin 5%, ticarcillin 0.66%, and amikacin
3% eye drops administered hourly in the eye. On day 2,
the bacterium was identiﬁed as Pseudomonas aeruginosa and
antibiotic disc sensitivity testings revealed that the organism
was sensitive to most of antibiotics including ticarcillin,
amikacin, ciproﬂoxacin, and ceftazidime. Initial treatment
was changed to ciproﬂoxacin 0.3% (Ciloxan, Alcon, France),
ticarcillin 0.66%, and amikacin 3% (prepared by the hospital
pharmacy). An amoebic polymerase chain reaction (PCR)
gave negative results. Six days after admission, ulcer size and
hypopyonwerereduced,andthepatientwasdischargedfrom
hospital but prescribed to continue the topical antibiotic
treatment at home, every 4 hours.
The patient represented to the emergency unit, on day
13. Ulcer size had increased and hypopyon was observed
again. It was decided to hospitalize the patient again. Initial
treatment with topical vancomycin, ticarcillin, and amikacin
eye drops was restarted. On day 16, due to the ineﬃcacy of
this treatment, corneal scrapings were performed again for
bacterial culture and amoebic PCR, results of which were
both negative. Three weeks after the start of the infection,
the clinical situation was still worsening and the integrity of
the eye was compromised (Figure 1).
At this stage, a new therapeutic strategy was pre-
scribed; topical and intravenous ceftazidime were included
in the antimicrobial strategy. A fortiﬁed 5%-ceftazidime
ophthalmic solution was prepared by the hospital pharmacy.
It was instilled hourly in the infected eye. Additionally, a 1-g
intravenous injection of ceftazidime (Fortum, GSK, Paris)
was administered every 8 hours in association with 250-
mg oral acetazolamide [1] (Diamox, Sanoﬁ-Aventis, France)
every 24 hours. After 2 days (Day 23), clinical improvement2 Journal of Ophthalmology
Figure 1: Three weeks after initial presentation, corneal ulcer
associated with an intense inﬂammation and a dense hypopyon
were still observed.
Figure 2: Four weeks after the start of ceftazidime treatment,
we noticed a central corneal scar, absence of hypopyon, and no
evidence of active keratitis.
was shown according to corneal abscess regression and
hypopyon disappearance.
One week after the initiation of this late treatment (Day
30), clinical improvement allowed a cessation of the intra-
venousceftazidimeandareductioninthefrequencyofinstil-
lation of the topical fortiﬁed antibiotics. Ceftazidime was
tapered gradually over the next three weeks and eventually
stopped.Abscessregressionandhypopyondisappearanceare
illustrated by Figure 2.
Four months after the ﬁrst hospitalization, the left eye
visual acuity was 0.6L. There was evidence of central corneal
scarring without inﬂammation or neo-vessels (Figure 3).
2. Discussion
P. aeruginosa is the predominant Gram-negative bacterium
that infects the cornea. For many years, keratitis caused
by Pseudomonas has been commonly associated with the
Figure 3: A slit lamp photograph of the left eye 4 months
after initial presentation illustrates a central corneal scar without
inﬂammation or neovessels.
wearing of soft contact lenses [2], and it has recently been
reported that the wearing of contact lenses was the most
commonriskfactorforkeratitisandthatthemostcommonly
isolated organism was P. aeruginosa [3, 4]. Even in compliant
patients [5], standard lens care hygiene precautions are
probably not suﬃcient for preventing the development of
sporadic corneal infections.
Inthiscase,topicalbroad-spectrumantibioticswereused
initially in the empiric treatment [6, 7] and then switched,
once the results of cultures and antibiotic sensitivity patterns
were recovered from the laboratory. Two weeks after the start
of treatment, scrapings were performed again but, this time,
without pathogen recovery.
Threeweeksafterﬁrstadmissiontohospital,theintegrity
of the eye was compromised. At this stage, a topical
and intravenous ceftazidime regimen was started [1, 8].
Ceftazidime is a third-generation cephalosporin antibiotic,
withanextendedspectrumofactivityagainstGram-negative
bacteria, especially Pseudomonas spp. It is one of the
most eﬀective antibiotics against P. aeruginosa, the organ-
ism isolated after ﬁrst corneal scrapings. Topical fortiﬁed
5%-ceftazidime eye drops (50mg/mL) were prepared (in
an appropriate compounding aseptic containment isolator
maintaining an ISO 5 air quality environment) in saline,
following data showing a short-term stability (4 days at
4◦C) [9]. Ceftazidime pharmacokinetic properties in healthy
volunteersgivesatisfactorypenetrationfeaturesoftheantibi-
otic into aqueous humor; a mean concentration of 11 ±
4μg/mL (after a 2-g ceftazidime infusion), corresponding to
a penetration ratio of 19%, has been reported [8].
This case report illustrates the fact that concentrations
obtained with topical antibiotic treatment alone, even if
delivered on an inﬂamed cornea may not be suﬃcient
to eradicate intermediate or poorly sensitive Pseudomonas
strains. In such cases, it is necessary to add systemic
treatment to the topical antibiotic regimen. We also decided
to enhance the penetration of the antibiotic in the anteriorJournal of Ophthalmology 3
chamber by the means of an unusual but useful phar-
macokinetic interaction with acetazolamide. Concomitant
administration of acetazolamide was decided owing to a
previous report demonstrating that it increases aqueous
humor concentration of intravenous ceftazidime. It has been
established that 2, 4, and 6 hours after a 2-g ceftazidime
infusion, antibiotic concentration in aqueous humor was
signiﬁcantly increased after acetazolamide (250mg for every
6 hours) coadministration [1].
Addition of acetazolamide, a carbonic anhydrase
inhibitor (CAI), in the therapeutic regimen, allows an
increase in the concentration of ceftazidime in the anterior
chamber by a factor 2 to 5. For instance, 2 hours after the
end of the infusion, concentrations of 4.26 ± 1.75mg/L and
22.4 ± 16.6mg/L were measured, respectively, in aqueous
humor in patients without or with acetazolamide treatment
[1]. For P. aeruginosa, ceftazidime (Minimal Inhibitory
Concentrations) MICs range from 2 to 6mg/L [10]. These
data suggest that the use of acetazolamide, by increasing the
drug concentration at its site of action 2-to 5-fold, is likely to
allow exceeding MICs for most P. aeruginosa strains.
In the present case, the length of the treatment was
one week for intravenous ceftazidime associated with aceta-
zolamide and one month for topical ceftazidime. The
choice of acetazolamide was based on its speciﬁc phar-
macological properties on the electrolytic balance in body
ﬂuids. Carbonic anhydrase has the property to reversibly
accelerate the reaction between carbonic anhydride (CO2)
and water (H2O). The presence of this enzyme in ocular
structures, including the ciliary body processes, and the
high concentration of bicarbonate in the aqueous humor
allow an opportunity for CAI to play an important role
in ionic changes in both posterior and anterior chambers.
Within the anterior chamber, besides lowering intraocular
pressure, CAI will also lower the amount of bicarbonate
(HCO3
−) production, [11] thus decreasing the pH. As a
consequence of this phenomenon, the state of ionization of
n u m e r o u sp h a r m a c o l o g i c a la g e n t si sm o r eo rl e s sm o d i ﬁ e d .
CAI will increase the ionization of basic molecules and
decrease the ionization of acidic drugs. It is well known
that nonionized molecules can easily diﬀuse across cell
membranes. In contrast, the ionized molecules are usually
unable to penetrate the lipid membrane because of their low
lipid solubility. Ceftazidime, with two carboxylic moieties,
behaves as a weak acidic molecule in biological ﬂuids.
After CAI intake, the amount of bicarbonate in aqueous
humor is lowered and the ﬂuid is acidiﬁed as a result. In
such conditions, ceftazidime ionization decreases, and its
intracellular penetration is then enhanced.
Further investigations and additional cases must be
reviewed before deﬁnite conclusions can be made as to the
improvementinceftazidimeeﬀectivenesswhenadministered
with acetazolamide, to treat severe keratitis caused by P.
aeruginosa.
Theanteriorchamberisacrucialtargetwhenconsidering
that most ocular infections start with germ penetration
through the cornea, followed by colonization of the aqueous
humor. In various acute microbial keratitis, the use of aceta-
zolamide could be relevant when the antibiotic treatment
is comprised of a weak acidic molecule (carbenicillin, ticar-
cillin). In such cases, acetazolamide adjunction to antibiotic
treatment could be an easy and inexpensive way to obtain
an increase in antibiotic concentration within the anterior
chamber, allowing the antibiotic MIC to be reached more
easily and facilitating improvement or healing.
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